Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

December 31, 2010

Conditions
Advanced Solid Cancers
Interventions
DRUG

CKD-810, Taxotere inj.

Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.

DRUG

CKD-810, Taxotere inj.

Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.

Trial Locations (7)

Unknown

Gachon University Gil Hospital, Inchon

The Catholic university of KOREA, Seoul ST. Mary's Hospital, Seoul

The Korea University Anam Hospital, Seoul

Ajou University Hospital, Suwon

Dongsan Medical Center, Keimyung University, Taegu

Yeoungnam University Hospital, Taegu

Ulsan University Hospital, Ulsan

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY